Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008764 | 0.94 | AKT1 (0.40) | AKT1GPR84METCYP11B1HSP90AA1 | |
| SCHEMBL13008378 | 0.91 | AKT1 (0.44) | AKT1METCYP11B1HSP90AA1ALOX5 | |
| SCHEMBL13427524 | 0.91 | CYP11B1 (0.34) | AKT1CYP11B1SOS1 | |
| SCHEMBL13427604 | 0.90 | AKT1 (0.41) | AKT1GPR84METHSP90AA1GSTP1 | |
| SCHEMBL13008367 | 0.89 | AKT1 (0.43) | AKT1METHSP90AA1SOS1 | |
| SCHEMBL13427598 | 0.89 | AKT1 (0.40) | AKT1GPR84METHSP90AA1SOS1 | |
| SCHEMBL13427595 | 0.88 | AKT1 (0.44) | AKT1GPR84METHSP90AA1SOS1 | |
| SCHEMBL13427570 | 0.88 | AKT1 (0.42) | AKT1METCYP11B1HSP90AA1GSTP1 | |
| SCHEMBL13427597 | 0.87 | AKT1 (0.41) | AKT1METCYP11B1HSP90AA1ALOX5 | |
| SCHEMBL13427565 | 0.87 | AKT1 (0.41) | AKT1METCYP11B1HSP90AA1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256176-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-03-04 | — | — | US | disclosed |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-03-04 | — | — | US | disclosed |
| EP-2141214-A2 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | RPL36, RPL39, RPL36A | AKT1 3459/4885GPR84 1648/4885MET 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.